agreement
access
health
care
richard
nicola
developed
newly
industrialized
country
question
related
whether
system
universal
universality
principle
welfare
service
available
right
according
need
restricted
individual
ability
pay
one
five
essential
element
national
economic
research
associate
prototype
also
consistent
world
organization
goal
poorest
developing
may
arise
due
lack
resource
provide
even
rudimentary
understandmg
cause
problem
complex
exercise
incorrect
suggest
examined
solely
term
pharmaceutical
especially
impact
aspect
intellectual
property
first
existing
product
treat
ten
thousand
thirty
diagnosed
disease
two-thirds
known
medcal
cannot
treated
cured
drug
second
protection
encourages
innovation
key
fictor
contributes
improved
promoting
development
new
mehcines
growth
generally
encouraging
implement
effective
regime
public
policy
provides
substantial
benefit
firm
likely
launch
incentive
acknowledged
vice
president
washington
office
inc
analyst
sydney
australia
support
&om
manufacturen
america
grateiuily
hofflneyer
finumng
core
kluwer
academic
publisher
dordrecht
netherlands
vol
chapter
otto
stamm
rigkts
competitive
strufegy
international
mairs
council
global
dimension
cf
science
technology
academy
press
rozek
ruth
berkowitz
efecects
fke
price
prodtut-
raising
bill
march
search
solution
incidence
life
expectancy
afhca
nearly
million
people
living
dramatic
associated
african
would
implementing
encourage
prevent
moreover
apply
approximately
percent
commercially
many
year
remaining
often
subject
therapeutic
competition
case
consumer
receive
marketplace
way
lengthy
waiting
time
heart
surgery
canada
reduce
quality
increase
pain
general
discomfort
patient
working
grey-labor
market
mexico
allowed
enter
social
security
example
lllustrate
barrier
exist
restrict
availability
classified
six
area
physical
informational
financial
political
socialand
ethnic
examining
fiom
thts
broader
perspective
help
focus
recommendation
reform
greatest
form
facility
personnel
primary
providing
live
remote
rural
elderly
mentally
physically
handicapped
difficulty
accessing
within
urban
environment
inadequate
merck
company
official
suggested
usually
considered
sigtllficant
risk
patent
see
michael
reich
ed
strategiesfor
tropical
treatment
expetiences
prariquantel
action
programme
division
control
january
bank
indicator
greg
tobias
profecfion-he
argentinian
divide
scrip
magazine
november
adktion
two
hundred-fifcy
chemical
entity
list
protected
rapp
benejts
cost
october
infrastructure
place
meet
level
demand
private
construct
insufficient
growing
population
expanding
unable
larger
south
korea
experienced
expanded
coverage
basic
road
transportation
education
inhibit
mstribution
physician
skewed
toward
center
select
location
practice
located
financing
without
appropriate
regulation
fachties
concentrated
densely
populated
leaving
rest
adequate
specialist
appropriately
provided
centralized
basis
economy
scale
issue
structure
implies
longer
travel
postpone
seelung
rationing
constraint
use
budget
tax
insurance
line
shortage
stafâ‚¬
particular
imperfect
information
affect
fail
tuberculosis
hepatitis
hypertension
know
particularly
minority
immigrant
africa
vertical
program
asch
gelberg
leake
fo
delay
obtaining
carefor
internal
medicine
los
angeles
cahfomia
funded
different
source
identifying
provider
actually
operate
integrated
network
proper
economical
self-mehcation
poorly
informed
lead
ineffective
utilization
illness
diarrhea
inappropriately
antibiotic^^
always
aware
cost-effective
therapy
addition
preference
dosage
influence
choice
generic
prefer
brand
name
unsure
safety
reliability
pirated
therefore
government
establish
efficacy
standard
expiration
annual
spending
ministry
afiican
per
caput
region
costly
purchase
significance
differs
importance
dependmg
april
jawahar
bapna
chakra
tripathi
uma
tekur
utilisation
pattern
third
study
found
nigeria
child
received
antibiotic
isenalumbe
osawaru
polypharmacy
burden
bartier
medical
drug-
oriented
journal
pp
cited
et
al
ibid
another
sri
lanka
used
angunawela
diwan
tomson
experimental
evaluanon
injomnhon
oti
prescribing
utilizafion
karolinska
institute
stockholm
bapma
eta
brazil
reluctant
prescribe
praziquantel
schistosomiasis
expensive
le
oxamniquine
reason
reluctance
complaint
large
size
tablet
difficult
swallow
supra
footnote
bruneton
favre
fontaine
competitionfor
promotion
participatim
methodfor
andfor
wide
web
page
viable
alternative
united
kingdom
whereas
afiica
last
resort
offer
comparable
choose
&scriminate
adjustment
compensate
insurer
high
afflicted
chronic
condition
denying
subtle
appear
person
request
dlfficult
locate
able
full
relatively
co-payments
unofficial
side
payment
prevalent
central
eastern
european
make
discourage
assign
priority
sufficient
build
necessary
improve
status
spendmg
sanitation
positive
factor
consider
clean
safe
poverty
stronger
correlation
water
expenditure
investment
preventing
significant
treating
group
illegal
entitled
emergency
maternal
italy
seek
fear
dlscovery
immigration
authority
rule
labor
outside
grey-market
worker
contribute
excluded
data
respectively
healthcare
news
syfem
report
prepared
language
understand
&fficulty
illiterate
get
admmistrative
homosexual
addict
greater
dificulty
discriminatory
attitude
gender
religion
islamic
state
woman
since
female
certain
aborigine
cultural
difference
perception
romany
gypsy
romania
empirical
proposition
raise
thus
create
contrary
work
confirms
adopts
ipp
institutional
feature
single
buyer
fact
law
retroactive
already
restrain
instance
accurate
irrelevant
rather
focusing
industry
inhibiting
attempt
classify
underlying
really
mean
preventive
medicinefor
american
dffer
elsewhere
step
identify
set
formulate
country-specific
plan
sponsoring
important
realize
increasing
prevention
effect
nevertheless
improving
devote
addressing
severe
regard
designing
dramatically
aid
diagnosing
major